Volume 8, Issue 1 pp. 65-68
Full Access

The danger of ‘yellow dyes’ (tartrazine) to allergic subjects

I. NEUMAN

Corresponding Author

I. NEUMAN

Pediatric Allergy Unit, Pediatric Department and Laboratory, and Clinical Laboratories, Hasharon Hospital, Petah-Tiqva, Israel

Dr I. Neuman, Pediatric Allergy Unit, Hasharon Hospital, Petah-Tiqva, Israel.Search for more papers by this author
R. ELIAN

R. ELIAN

Pediatric Allergy Unit, Pediatric Department and Laboratory, and Clinical Laboratories, Hasharon Hospital, Petah-Tiqva, Israel

Search for more papers by this author
H. NAHUM

H. NAHUM

Pediatric Allergy Unit, Pediatric Department and Laboratory, and Clinical Laboratories, Hasharon Hospital, Petah-Tiqva, Israel

Search for more papers by this author
P. SHAKED

P. SHAKED

Pediatric Allergy Unit, Pediatric Department and Laboratory, and Clinical Laboratories, Hasharon Hospital, Petah-Tiqva, Israel

Search for more papers by this author
D. CRETER

D. CRETER

Pediatric Allergy Unit, Pediatric Department and Laboratory, and Clinical Laboratories, Hasharon Hospital, Petah-Tiqva, Israel

Search for more papers by this author
First published: January 1978
Citations: 31

Summary

Oral administration of 50 mg tartrazine to 122 patients with a variety of allergic disorders caused the following reactions: general weakness, heatwaves, palpitations, blurred vision, rhinorrhoea, feeling of suffocation, pruritus and urticaria.

There was activation of the fibrinolytic pathway as shown by reduction of plas-minogen with high pre-kallikrein and low kallikrein values. Reduction in complement activity (CH50) was seen in three out of sixteen reactions.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.